RecruitingNot ApplicableNCT07362654

Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease

Single-cell Study of the Systemic Immune Response to Controlled Gluten Intake in Pediatric Celiac Disease


Sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Enrollment

51 participants

Start Date

Jul 7, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study investigates how the immune system of children with celiac disease responds to controlled, small amounts of gluten. Children on a strict gluten-free diet are randomly assigned to receive either placebo, 50 mg of gluten, or 5 g of gluten once daily for three days, simulating real-life accidental exposure or dietary transgression. Blood samples are collected on Day 1 (before gluten intake) and Day 8 (five days after the last dose). Stool and urine samples are also collected for complementary analyses. Using single-cell ribonucleic acid (RNA) sequencing, T-cell receptor sequencing, microRNA profiling, and exploratory metabolomics, the study aims to characterize changes in immune cell populations and gene expression after gluten exposure. The objective is to determine whether even very small amounts of gluten induce measurable systemic immune responses and whether these responses differ according to the dose administered. Understanding these mechanisms may support the development of new biomarkers and improve clinical management of pediatric celiac disease.


Eligibility

Min Age: 8 YearsMax Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Collection of blood, stool and urine samples on Day 1 and Day 8., Gluten 5 g, and others for people with autoimmune diseases, celiac disease, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTPlacebo

Placebo preparation identical in appearance and administration schedule to gluten doses. Administered once daily on Days 1, 2, and 3. Used as the comparator. Participants and evaluators remain blinded to allocation.

DIETARY_SUPPLEMENTGluten 50 mg

Participants receive 50 mg of gluten once daily on Days 1, 2, and 3. This dose simulates accidental low-level gluten exposure in children with celiac disease. Participants and evaluators remain blinded to allocation.

DIETARY_SUPPLEMENTGluten 5 g

Participants receive 5 g of gluten once daily on Days 1, 2, and 3. This dose simulates a dietary transgression in children with celiac disease. Participants and evaluators remain blinded to allocation.

PROCEDURECollection of blood, stool and urine samples on Day 1 and Day 8.

In addition to blood samples, stool and urine samples will be collected for complementary analyses (including fecal gluten immunogenic peptides (GIP) and exploratory metabolomic assays)


Locations(1)

Hospital Regional Universitario de Málaga

Málaga, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07362654


Related Trials